PADCEV Support Solutions offers Benefits Investigation (BI) assistance to evaluate a patient's insurance coveragea for PADCEV® (enfortumab vedotin-ejfv).
After performing a BI, we will provide a Summary of Benefits that includes:
- The patient's insurance coverage for PADCEV
- Requirements for prior authorization or other coverage restrictions, if any
- Cost-sharing responsibilities, including the deductible, coinsurance or copayment, and out-of-pocket maximums
We will initiate a BI upon receipt of a completed Patient Enrollment Form.
Once BI is complete, we will send a Summary of Benefits.
PADCEV Support Solutions is a component of Astellas Pharma Support SolutionsSM.
aAstellas and Seagen do not guarantee third-party coverage, payment, or reimbursement for denied claims. Coverage and reimbursement vary significantly by payer, patient, and setting of care and are subject to change. Therefore, it is important that providers verify each patient's insurance coverage prior to initiating therapy. Each healthcare provider is ultimately responsible for determining coverage for individual patients.
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.